JPH09509646A - 多発性硬化症を治療する方法 - Google Patents
多発性硬化症を治療する方法Info
- Publication number
- JPH09509646A JPH09509646A JP7505635A JP50563595A JPH09509646A JP H09509646 A JPH09509646 A JP H09509646A JP 7505635 A JP7505635 A JP 7505635A JP 50563595 A JP50563595 A JP 50563595A JP H09509646 A JPH09509646 A JP H09509646A
- Authority
- JP
- Japan
- Prior art keywords
- necrosis factor
- tumor necrosis
- antibody
- tnf
- soluble
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preliminary Treatment Of Fibers (AREA)
- Spinning Or Twisting Of Yarns (AREA)
- Treatment Of Fiber Materials (AREA)
- Transplanting Machines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.哺乳動物の多発性硬化症を治療するための方法であって、多発性硬化症の効 果を軽減する抗腫瘍壊死因子抗体の治療上有効量を該哺乳動物に投与することを 含む方法。 2.該哺乳動物がヒトである、請求項1記載の方法。 3.該抗腫瘍壊死因子抗体を薬学上許容される担体中に含有させて投与する、請 求項2記載の方法。 4.抗腫瘍壊死因子抗体の治療上有効量をヒトの中枢神経系に直接投与する、請 求項2記載の方法。 5.抗腫瘍壊死因子抗体を膜内(intrathecally)に投与する、請求項4記載の方 法。 6.抗腫瘍壊死因子抗体がポリクローナル抗体である、請求項2記載の方法。 7.抗腫瘍壊死因子抗体がモノクローナル抗体である、請求項2記載の方法。 8.抗腫瘍壊死因子抗体が抗体断片である、請求項2記載の方法。 9.薬学的に許容される担体、及び多発性硬化症の効果を軽減する抗腫瘍壊死因 子抗体の多発性硬化症に対する治療上の有効量を含む医薬組成物。 10.該抗腫瘍壊死因子抗体がポリクローナル抗体である、請求項9記載の組成 物。 11.該抗腫瘍壊死因子抗体がモノクローナル抗体である、請求項9記載の組成 物。 12.該抗腫瘍壊死因子抗体が抗体断片である、請求項9記載の組成物。 13.哺乳動物の多発性硬化症を治療する方法であって、多発性硬化症の効果を 軽減する可溶性腫瘍壊死因子受容体の治療上有効量を該哺乳動物に投与すること を含む方法。 14.該哺乳動物がヒトである、請求項13記載の方法。 15.該可溶性腫瘍壊死因子受容体を薬学上許容される担体中に含有させて投与 する、請求項14記載の方法。 16.可溶性腫瘍壊死因子受容体の治療上有効量を中枢神経系に直接投与する、 請求項14記載の方法。 17.該可溶性腫瘍壊死因子受容体を膜内(intrathecally)に投与する、請求 項14記載の方法。 18.該可溶性腫瘍壊死因子受容体がその結合性断片である、請求項14記載の 方法。 19.該可溶性腫瘍壊死因子受容体が可溶性ヒトp55−腫瘍壊死因子受容体で ある、請求項14記載の方法。 20.該可溶性ヒトp55−腫瘍壊死因子受容体がその結合性断片である、請求 項19記載の方法。 21.薬学的に許容される担体、及び多発性硬化症の効果を軽減する可溶性腫瘍 壊死因子受容体の多発性硬化症に対する治療上の有効量を含む医薬組成物。 22.該可溶性腫瘍壊死因子受容体がその結合性部分である、請求項21記載の 組成物。 23.該可溶性腫瘍壊死因子受容体が可溶性ヒトp55−腫瘍壊死因子受容体で ある、請求項21記載の組成物。 24.該可溶性ヒトp55−腫瘍壊死因子受容体がその結合性部分である、請求 項23記載の組成物。 25.ヒトの多発性硬化症を治療する方法であって、抗腫瘍壊死因子抗体の治療 上有効量を該ヒトの中枢神経系に直接投与することを含む方法。 26.哺乳動物の多発性硬化症を治療する方法であって、腫瘍壊死因子生産、そ の効果及び/又は腫瘍壊死因子受容体シグナルトランスダクションを阻止するこ とができる化合物の治療上有効量を該哺乳動物に投与することを含む方法。 27.治療、例えば多発性硬化症の治療に使用するための、(1)腫瘍壊死因子 の生産またはその効果及び/又は(2)腫瘍壊死因子受容体シグナルトランスダ クション、を阻止することができる物質。 28.治療、例えば多発性硬化症の治療に使用するための、(1)腫瘍壊死因子 の生産またはその効果及び/又は(2)腫瘍壊死因子受容体シグナルトランスダ クション、を阻止することができる物質の使用。 29.該物質が請求項9〜請求項12または請求項21〜請求項24いずれか1 項に記載の組成物を含むものである、請求項27記載の物質又は請求項28記載 の使用。 30.該治療が請求項1〜請求項8、請求項13〜請求項2 0又は請求項25〜請求項26いずれか1項に記載の方法を含むものである、請 求項27〜29いずれか1項に記載の物質又は使用。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/GB1993/001614 WO1995003827A1 (en) | 1993-07-30 | 1993-07-30 | Method for treating multiple sclerosis |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH09509646A true JPH09509646A (ja) | 1997-09-30 |
Family
ID=10729416
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP7505635A Ceased JPH09509646A (ja) | 1993-07-30 | 1993-07-30 | 多発性硬化症を治療する方法 |
Country Status (11)
Country | Link |
---|---|
US (1) | US5958409A (ja) |
EP (2) | EP0710121B1 (ja) |
JP (1) | JPH09509646A (ja) |
AT (1) | ATE196849T1 (ja) |
AU (1) | AU4719093A (ja) |
DE (1) | DE69329558T2 (ja) |
DK (1) | DK0710121T3 (ja) |
ES (1) | ES2153384T3 (ja) |
GR (1) | GR3035196T3 (ja) |
PT (1) | PT710121E (ja) |
WO (1) | WO1995003827A1 (ja) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
US6270766B1 (en) | 1992-10-08 | 2001-08-07 | The Kennedy Institute Of Rheumatology | Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease |
US7070783B1 (en) * | 1995-05-09 | 2006-07-04 | The Mathilda And Terence Kennedy Institute Of Rheumatology | Small molecular weight TNF receptor multimeric molecule |
US6225300B1 (en) | 1995-07-14 | 2001-05-01 | Applied Research Systems Ars Holding Nv | TNF receptor and steroid hormone in a combined therapy |
US7012060B1 (en) | 1995-07-14 | 2006-03-14 | Applied Research Systems Ars Holding N.V. | TNF receptor and steroid hormone in a combined therapy |
US7608262B2 (en) | 1996-02-16 | 2009-10-27 | The Kennedy Institute Of Rheumatology | Methods of preventing or treating thrombosis with tumor necrosis factor antagonists |
TW555765B (en) | 1996-07-09 | 2003-10-01 | Amgen Inc | Low molecular weight soluble tumor necrosis factor type-I and type-II proteins |
US6660843B1 (en) * | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
IL127851A0 (en) * | 1998-12-30 | 1999-10-28 | Applied Research Systems | Inhibition of TNF activity |
US8119127B2 (en) * | 1999-02-24 | 2012-02-21 | Tact Ip, Llc | Cytokine antagonists for neurological and neuropsychiatric disorders |
US6982089B2 (en) * | 1999-02-24 | 2006-01-03 | Tact Ip, Llc | Cytokine antagonists for neurological and neuropsychiatric disorders |
USRE45976E1 (en) * | 1999-02-24 | 2016-04-19 | Tact Ip, Llc | Methods of inhibiting the action of TNF for neurological conditions by administering etanercept intrathecally |
WO2001013945A1 (en) * | 1999-08-23 | 2001-03-01 | Biocrystal Ltd. | Methods and compositions for immunotherapy of b cell involvement in promotion of a disease condition comprising multiple sclerosis |
DK1401498T3 (da) * | 2001-05-30 | 2011-11-21 | Genentech Inc | Anti-NGF-antistoffer til behandlingen af forskellige sygdomme |
US20050175585A1 (en) * | 2001-06-11 | 2005-08-11 | Transition Therapeutics Inc. | Combination therapies using vitamin B12 and interferon for treatment of viral proliferative and inflammatory disesases |
CA2487039A1 (en) * | 2001-06-11 | 2002-12-19 | Transition Therapeutics Inc. | Combination therapies using vitamin b12 and interferon for treatment of viral, proliferative and inflammatory diseases |
EP2409569B1 (en) * | 2002-02-20 | 2017-08-16 | Emisphere Technologies, Inc. | Method for administering GLP-1 molecules |
US9028822B2 (en) | 2002-06-28 | 2015-05-12 | Domantis Limited | Antagonists against TNFR1 and methods of use therefor |
WO2004050683A2 (en) | 2002-12-02 | 2004-06-17 | Abgenix, Inc. | Antibodies directed to tumor necrosis factor and uses thereof |
US7101978B2 (en) | 2003-01-08 | 2006-09-05 | Applied Molecular Evolution | TNF-α binding molecules |
US7435799B2 (en) | 2004-01-08 | 2008-10-14 | Applied Molecular Evolution | TNF-α binding molecules |
US8236306B2 (en) * | 2004-12-18 | 2012-08-07 | Edward Lewis Tobinick | Methods to facilitate transmission of large molecules across the blood-brain, blood-eye, and blood-nerve barriers |
JP2009531295A (ja) * | 2006-02-22 | 2009-09-03 | ユニバーシティ オブ チューリッヒ | 自己免疫疾患又は脱髄疾患を処置するための方法 |
HUE040044T2 (hu) | 2013-03-14 | 2019-02-28 | Alkermes Pharma Ireland Ltd | Fumarátok prodrugjai, és azok alkalmazása különbözõ betegségek kezelésében |
US8669281B1 (en) | 2013-03-14 | 2014-03-11 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
US9604922B2 (en) | 2014-02-24 | 2017-03-28 | Alkermes Pharma Ireland Limited | Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL98078A0 (en) * | 1991-05-07 | 1992-06-21 | Yeda Res & Dev | Pharmaceutical compositions comprising an anticytokyne |
WO1991002078A1 (en) * | 1989-08-07 | 1991-02-21 | Peptide Technology Ltd | Tumour necrosis factor binding ligands |
EP1132471A3 (de) * | 1989-09-12 | 2001-11-28 | F. Hoffmann-La Roche Ag | TNF-bindende Proteine |
US5656272A (en) * | 1991-03-18 | 1997-08-12 | New York University Medical Center | Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies |
DE4202665A1 (de) * | 1992-01-28 | 1993-07-29 | Schering Ag | Prostacyclin- und carbacyclinderivate als mittel zur behandlung von multipler sklerose |
-
1993
- 1993-07-30 EP EP93917954A patent/EP0710121B1/en not_active Expired - Lifetime
- 1993-07-30 EP EP99203261A patent/EP1004312A1/en not_active Ceased
- 1993-07-30 WO PCT/GB1993/001614 patent/WO1995003827A1/en active IP Right Grant
- 1993-07-30 US US08/586,917 patent/US5958409A/en not_active Expired - Lifetime
- 1993-07-30 AU AU47190/93A patent/AU4719093A/en not_active Abandoned
- 1993-07-30 PT PT93917954T patent/PT710121E/pt unknown
- 1993-07-30 DK DK93917954T patent/DK0710121T3/da active
- 1993-07-30 AT AT93917954T patent/ATE196849T1/de active
- 1993-07-30 JP JP7505635A patent/JPH09509646A/ja not_active Ceased
- 1993-07-30 DE DE69329558T patent/DE69329558T2/de not_active Expired - Lifetime
- 1993-07-30 ES ES93917954T patent/ES2153384T3/es not_active Expired - Lifetime
-
2001
- 2001-01-10 GR GR20010400014T patent/GR3035196T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
US5958409A (en) | 1999-09-28 |
GR3035196T3 (en) | 2001-04-30 |
EP1004312A1 (en) | 2000-05-31 |
WO1995003827A1 (en) | 1995-02-09 |
ES2153384T3 (es) | 2001-03-01 |
EP0710121A1 (en) | 1996-05-08 |
ATE196849T1 (de) | 2000-10-15 |
PT710121E (pt) | 2001-04-30 |
AU4719093A (en) | 1995-02-28 |
DE69329558D1 (de) | 2000-11-16 |
EP0710121B1 (en) | 2000-10-11 |
DE69329558T2 (de) | 2001-05-31 |
DK0710121T3 (da) | 2001-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH09509646A (ja) | 多発性硬化症を治療する方法 | |
CA2146647C (en) | Treatment of autoimmune and inflammatory disorders | |
EP0936923B1 (en) | SUPPRESSION OF TNFalpha AND IL-12 IN THERAPY | |
RU2607022C2 (ru) | Способы и композиции для лечения волчанки | |
JP2001502325A (ja) | 免疫調整の方法および組成物 | |
JPH09507074A (ja) | Cd40を発現する腫瘍細胞を特徴とする疾患の予防又は治療方法 | |
JP2646114B2 (ja) | ガンマインターフェロンに対する拮抗物質を用いるmhc関連自己免疫疾患を制御するための方法および投与形態 | |
US20210017264A1 (en) | Use of binding molecule specifically binding to precursor of brain-derived neurotrophic factor | |
WO1995009652A1 (en) | Treatment of autoimmune and inflammatory disorders | |
JP2018104424A (ja) | 認知機能改善剤 | |
JP2852705B2 (ja) | 自己免疫疾患の治療 | |
JPH09502184A (ja) | 体液性免疫の持続性抑制方法 | |
KR100333148B1 (ko) | 당뇨질환예방제및치료제로서사용되는Vα14Jα281을함유하는가용성T-세포수용체α쇄및유도체 | |
JPH11501283A (ja) | I型インターフェロンに対する中和活性を有する、インターフェロンレセプターに対するモノクローナル抗体を含んでなる医薬組成物 | |
US20020068057A1 (en) | Treatment of autoimmune and inflammatory disorders | |
JP6845237B2 (ja) | 抗−ヒトil−3抗体、il−3の高められた発現又はレベルに関連する疾患又は機能障害へのそれらの使用、及びヒトil−3の検出方法へのそれらの使用 | |
WO2001072334A2 (en) | Methods for treating disease with antibodies to cxcr3 | |
JPH10508831A (ja) | ビタミンb12/トランスコバラミンiiレセプターおよび結合部位に対する抗レセプターおよび増殖阻止剤 | |
US20230212284A1 (en) | Immune Response Suppressor | |
TWI825131B (zh) | Htlv-1關聯性脊髓病(ham)之治療或預防劑、及ham之治療方法 | |
KR20230142834A (ko) | 항-cd38 항체 및 이의 용도 | |
CN114901313A (zh) | 急性期的视神经脊髓炎的预防或治疗剂 | |
CN114945385A (zh) | 痴呆症的预防或治疗剂 | |
CN116867807A (zh) | Siglec-15结合蛋白的制备及其用途 | |
TW202012439A (zh) | 抗-唾液酸結合性類免疫球蛋白凝集素之抗體、包含該抗體之藥學組合物及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040330 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20040630 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20040816 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20041108 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20041214 |